Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2025-12-03 00:00:00 ET · period of report 2025-12-01 · accession 0001943192-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-03 | 2025-12-01 | TVTX | Cline Christopher R. | CFO | S - Sale+OE | $35.01 | -20.0K | 92.1K | -18% | -$700.2K |
| D | 2025-12-03 | 2025-12-01 | TVTX | Cline Christopher R. | CFO | M - OptEx | $16.23 | +20.0K | 112.1K | +22% | +$324.6K |
| D | 2025-12-03 | 2025-12-01 | TVTX | Cline Christopher R. | CFO | M - OptEx | $0.00 | -20.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-01 | S | D | 20,000 | $35.01 | 92,083 | D | — | — | (F2) The weighted average sale price for the transaction reported was $35.0101, and the range of prices were between $34.64 and $35.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 2 | Common | Common Stock | 2025-12-01 | M | A | 20,000 | $16.23 | 112,083 | D | — | — | |
| 3 | Derivative | Employee stock option (right to buy) | 2025-12-01 | M | D | 20,000 | $0.00 | 0 | D | $16.23 · — to 2026-05-19 | 20,000 Common Stock | (F3) The stock option is fully vested and exercisable. |